Hepatitis C

  title={Hepatitis C},
  author={John B. Wong},
  • J. Wong
  • Published 2012
  • Medicine
  • PharmacoEconomics
Chronic hepatitis C virus (HCV) infection affects 170 million individuals worldwide. As it is detected incidentally through the evaluation of liver function tests or at the time of blood donor testing, it is usually clinically silent until the advanced stages of liver disease have occurred, when treatment is less effective and shortages of donor liver organs limit the therapeutic options. Combination therapy with ribavirin and pegylated interferon has resulted in sustained viral negative… 

Estimation of average diagnosis and treatment costs of hepatitis C

The average cost of diagnosis and treatment of hepatitis C among patients based on their treatment regime, during the one course of treatment and six-month after stopping that is estimated.

The role of insurance providers in supporting treatment and management of hepatitis C patients

Hepatitis C virus disease requires serious policies and affordable insurance coverage and the expansion of coverage by private payers seems able to generate positive spillover benefits to public insures.

[Extrahepatic manifestations in chronic hepatitis C infected patients].

The authors summarize the main extrahepatic manifestations of chronic hepatitis C, as well as treatment possibilities, to improve the recognition in the era of the new effective direct antiviral agents.

A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.

This work sought to address challenges posed by comorbidities in patients with chronic HCV infection and limitations within the health care system, and recommend solutions to maximize the public benefit from ACA and the new drug regimen.

Awareness of Viral Hepatitis B and C Infection among First Year Medical Sciences Students in Jazan University

It was found that more than half of the students (64.4%) had basic awareness about hepatitis B and C infection as well as about symptoms, and females depicted higher base knowledge regarding mode of transmission, treatment and vaccination awareness.

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

CostsofaPublicHealthModelto IncreaseReceiptofHepatitis-Related ServicesforPersonsWithMentalIllness

Delivery of hepatitis and HIV public health services to persons with serious mental illness in outpatient mental health settings can be as cost-effective as similar interventions for other at-risk populations.

AWindowofOpportunity:MaximizingtheEffectiveness ofNewHCVRegimensintheUnitedStatesWiththe ExpansionoftheAffordableCareAct

Challenges posed by comorbidities in patients with chronic HCV infection and limitations within the health care system are addressed, and solutions to maximize the public benefit from ACA and the new drug regimen are recommended.



Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions.

Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection

The substantial prevalence of abnormal liver histology among asymptomatic persons is a provocative but incomplete rationale for screening for HCV, and the prevalence of infection and the effectiveness of treatment are also important considerations.

Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C

A decision analytic model was developed to project the immediate responses to treatment and predict the long-term outcomes on the basis of current natural history data to determine whether treatment of histologically mild chronic hepatitis C with a single 6-month course of interferon-2b would affect life expectancy and lifelong costs.

Natural history of hepatitis C.

Treatment of Chronic Hepatitis C Virus Infection

It is now possible to achieve a cure in nearly 50% of the patients with this infection, and a higher rate of response has been achieved by using the combination of interferon and ribavarin.

Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment

For coinfected patients with dually‐active HBV/HCV, the optimal regimen for therapy remains unclear although adding oral nucleos(t)ide analogs to pegylated IFN and ribavirin seems a reasonable empiric option.

Treatment of chronic hepatitis C virus infection - Dutch national guidelines.

This guideline is the establishment of practical guidelines in the evaluation and antiviral treatment of patients with chronic hepatitis C virus (HCV) infection, which includes recommendations for the initial evaluation of patients, the choice and duration of antiviral therapy and the follow-up after antiviral Therapy.

Combination Therapy for Hepatitis C Infection

The public health implications of HCV infection have only recently been widely appreciated, as a result of epidemiologic studies that pointed out the magnitude of infection and an alarming increase in morbidity and mortality due to HCV-related disease.

Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C

  • S. Vento
  • Medicine, Biology
    Journal of viral hepatitis
  • 2000
The high frequency of fulminant hepatitis in patients with HAV/HCV coinfection contrasts with other surveys, although a large Centers for Disease Control and Prevention survey demonstrated that HAV infection in Patients with pre‐existing chronic liver disease (CLD) is associated with increased mortality.